Insight

Nicholas Sarlis: Dr Luis Raez succinctly describes recently reported results from key clinical trials in NSCLC patients

Photo from Nicholas Sarlis / LinkedIn

Apr 1, 2024, 12:55

Nicholas Sarlis: Dr Luis Raez succinctly describes recently reported results from key clinical trials in NSCLC patients

Nicholas Sarlis, Chief Medical Officer at CLEARA Biotech BV, shared a post on LinkedIn:

“Dr. Luis E Raez, a renowned lung cancer expert and eminent ex-collaborator, succinctly describes recently reported results from key clinical trials in NSCLC patients, namely PAPILLON, CHECKMATE 77T, and KEYNOTE-671. The VuMedi video below also provides the meaning of these recent NSCLC updates along with their ‘positioning’ across a complex and rapidly evolving therapeutic landscape.”

Proceed to the video.
Source: Nicholas Sarlis/LinkedIn

cancer CheckMate-77T clinical trial Immunooncology immunotherapy Innovation KEYNOTE-671 Luis E. Raez Lung cancer Nicholas Sarlis NSCLC NSCLC patients NSCLC updates OncoDaily Oncology PAPILLON patient outcomes VuMedi

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer